Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The page has been updated to include new information about Non-muscle Invasive Bladder Cancer (NMIBC) and the involvement of Merck Sharp & Dohme LLC as collaborators, while significant details about a specific clinical trial have been removed.
    Difference
    49%
    Check dated 2025-04-16T14:37:00.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T09:40:42.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T23:36:48.000Z thumbnail image
  5. Check
    60 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T21:14:22.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T10:19:13.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T09:28:47.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.